Opinion|Videos|January 5, 2026
Molecular Testing and Identifying Appropriate Patients for Lenvatinib Plus Pembrolizumab in Endometrial Cancer
Author(s)Ramez N. Eskander, MD
Endometrial cancer treatment evolves with molecular insights, enhancing patient outcomes through tailored therapies and innovative clinical trials.
Advertisement
Episodes in this series
Ramez N. Eskander, MD, discusses the heterogenous nature of endometrial cancer and molecular testing being used to identify appropriate patients for specific treatments. He also highlights what study results have shown regarding molecular testing and optimal use of lenvatinib plus pembrolizumab in endometrial cancer.
Advertisement
Related to this article
Experts weigh continuous BTK inhibitors vs fixed-duration CLL therapy, highlighting TP53/17p risk, patient logistics, and subtle zanubrutinib–acalabrutinib tolerability differences.
The FDA converted the accelerated approval of pembrolizumab in TMB-high solid tumors to traditional approval, redefining TMB-high as at least 13 mut/Mb.
Following an end-of-phase 2 meeting with the FDA, Rgenta plans to start a phase 3 trial of oral RGT-61159 in adenoid cystic carcinoma in the first quarter of 2027.
The FDA granted fast track designation to SBE303, Samsung Bioepis’ investigational Nectin-4–targeting ADC, for advanced urothelial cancer following enfortumab vedotin.
The antibody-drug conjugate sofetabart mipitecan showed efficacy and safety, leading to selection of a phase 3 dose for the FRAmework-01 trial.
FDA grants orphan drug designation to onvansertib for relapsed or refractory CMML, boosting development of the PLK1 inhibitor after early signals of activity.
Findings highlight the need for individualized monitoring after discharge, despite low rates of severe toxicities.
During a live event, Robert Orlowski, MD, PhD, and participants discussed how access barriers, disease tempo, and bridging choices shape CAR T referral for a patient with early relapsed multiple myeloma.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
3
Real-World Data for Darolutamide vs Abiraterone Triplet Therapy in mHSPC
4
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
5